lutetium-177 macroaggregated albumin

Lutetium-177 macroaggregated albumin (LUTMA) is an investigational radiopharmaceutical consisting of the beta- and gamma-emitting radionuclide lutetium-177 conjugated to macroaggregated albumin (MAA) particles. Developed by researchers at Istanbul University-Cerrahpasa, LUTMA is designed for localized radionuclide therapy and imaging. It is administered via local injection, such as percutaneous intranodular injection for thyroid nodules or intra-articular injection for radiosynovectomy in inflammatory knee joints. The macroaggregated albumin particles, typically ranging from 10 to 120 µm in size, remain physically trapped at the injection site, allowing the beta emissions of lutetium-177 to deliver targeted radiation to reduce tissue volume while minimizing systemic exposure. Concurrently, the gamma emissions of lutetium-177 enable SPECT/CT imaging to confirm localization and monitor treatment progress.

Other names

177Lu-MAA177Lu-macroaggregated albuminlutetium (177Lu) macroaggregated albuminlutetium-177-labeled macroaggregated albuminlutetium177-labeled macroaggregated albuminlutetium 177-labeled macroaggregated albuminlutetium-177-labelled macroaggregated albuminlutetium177-labelled macroaggregated albuminlutetium 177-labelled macroaggregated albumin